NCT00027560 · OUTCOME

Acute Graft-versus-Host Disease Matched Related Patients

Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer · Source last updated 2013-01-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: participants
Interval / dispersion: Not reported
Time frame: up to 4 months post transplant

What was measured

Grade III-IV Acute Graft-versus-Host Disease

Analysis population: The number of matched related patients was analyzed as per protocol.

Groups in this outcome

Matched Related Patients

Not reported

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Matched Related Patients	25

Reported measurements

Source class 1

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Matched Related Patients	1	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
1

denoms

counts
group Id
OG000
value
25
units
Participants

description

Grade III-IV Acute Graft-versus-Host Disease

groups

id
OG000
title
Matched Related Patients

param Type

NUMBER

population Description

The number of matched related patients was analyzed as per protocol.

reporting Status

POSTED

time Frame

up to 4 months post transplant

title

Acute Graft-versus-Host Disease Matched Related Patients

type

PRIMARY

unit Of Measure

participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice